The Protein Subcellular Mislocalization in Human Cancers

PDF - Export to EndNote - PubMed Central XML format - PubMed Central XML format - PubMed Central XML format
PMID: 32153731 (PubMed) - PMCID: PMC7035461 - View online: PubReader
Volume 12, Issue 1, January-March , Page 1 to 1
Monday, December 2, 2019 :Received , Monday, December 2, 2019 :Accepted

  • Corresponding author Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tel: +98 21 22432020;
    - Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran


Several sets of proteins exist in eukaryotic cells wherein accurately localized in appropriate cellular locations containing plasma membrane, cytoplasm, nucleus and different membrane-enclosed organelles. Each protein is involved in distinct biochemical processes within the normal cell; therefore, the correct subcellular localization of protein is vital; as it provides the physiological context for protein function. However, protein mislocalization described as changing the appropriate subcellular localization of protein, was reported as a key feature of many proteins in a variety of human cancers 1. Mislocalization has important implications in alteration of activation condition, biological function and interaction network of a protein. Particularly,  the aberrant localization of tumor-suppressor proteins and proto-oncoproteins can alter their functions, respectively in either suppressing or supporting the cancer initiation in normal cells whereby cancer development, metastasis and drug resistance are increased 2

The mechanisms by which subcellular mislocalization is arising in cancer are various and deeply reviewed by Wang and Li 2. They can be described as modification of signals directing proteins into a particular location, dysregulation of sorter and transporter machinery, Endoplasmic Reticulum (ER) retention of misfolded proteins, aberrant endocytosis and vesicular trafficking, dysregulation of signal transduction and protein post-translational modification and so on 2.

The aberrant subcellular position of proteins in cancer tissues has been investigated broadly by antibody-based strategies including Immunohistochemistry (IHC). The major localization of sortilin on cell surface of ovarian carcinoma tissues rather than the main resident in ER-Golgi compartment of normal tissues was detected using IHC technique 3. The new method of Dissociable Antibody Microarray (DAMA) combining the power of IHC staining with protein microarray, provides the facility of high-throughput detection of protein subcellular localization 4.

The property of malignant cells in differently subcellular localization of proteins might be recruited as an intelligent strategy for detection of malignant but not normal cells in clinical diagnostic and prognostic applications 5.  For instance, fibromodulin, a type of proteoglycan resides in extracellular matrix, has been irregularly located on cell surface of Chronic Lymphocytic Leukemia (CLL) cells but not in normal samples by which a new CLL diagnostic biomarker appropriate for cell surface flow cytometric detection  might be suggested 6. Moreover, directly targeting of locations in where proteins are accumulated in cancer cells plus selecting the structural dissimilarities of proteins by biologic weapons help us to specifically eradicate malignant but not normal cells.

In conclusion, the subscellular mislocalization of proteins is a frequent event in cancers defined as an accessory approach for proliferation, survival and invasion of tumors. However, targeting and trapping proteins in specific cellular compartments has been conceptualized as a promising approach for diagnostic, prognostic and therapeutic clinical use.




References :
  1. Hung MC, Link W. Protein localization in disease and therapy. J Cell Sci 2011;124(Pt 20):3381-3392.   [PubMed]
  2. Wang X, Li S. Protein mislocalization: mechanisms, functions and clinical applications in cancer. Biochim Biophys Acta 2014;1846(1):13-25.   [PubMed]
  3. Hemmati S, Zarnani AH, Mahmoudi AR, Sadeghi MR, Soltanghoraee H, Akhondi MM, et al. Ectopic expression of sortilin 1 (NTR-3) in patients with ovarian carcinoma. Avicenna J Med Biotechnol 2009;1(2):125-131.   [PubMed]
  4. Wang Y. Immunostaining with dissociable antibody microarrays. Proteomics 2004;4(1):20-26.   [PubMed]
  5. Sajic T, Ciuffa R, Lemos V, Xu P, Leone V, Li C, et al. A new class of protein biomarkers based on subcellular distribution: application to a mouse liver cancer model. Scientific Reports 2019;9(1):6913.
  6. Farahi L, Ghaemimanesh F, Milani S, Razavi SM, Hadavi R, Bayat AA, et al. GPI-anchored fibromodulin as a novel target in chronic lymphocytic leukemia: diagnostic and therapeutic implications. Iranian J Immunology 2019;16(2):127-141.

Home | About us | Contact us | Search | Site Map | Feeds | Rights & Permissions

"Avicenna Journal of Medical Biotechnology - A.J.M.B." is owned, published, and copyrighted by © 2020 Avicenna Research Institute. (pISSN: 2008-2835 .::. eISSN: 2008-4625)

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Creative Commons License